
Staying One Step Ahead of Resistance
How bacteria develop resistance to antisense antibiotics - and how future therapies can be designed to reduce the risk of resistance

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.
This year's TWINCORE Symposium
Pathways to infection resilience
will take place on 3 - 4 September.

How bacteria develop resistance to antisense antibiotics - and how future therapies can be designed to reduce the risk of resistance

A team of researchers from Hamburg, Berlin, Göttingen and Hannover has provided evidence of possible cross-protection offered by an already authorised Zaire Ebola virus vaccine.

Memory B cells play a key role in adapting to new coronavirus variants
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Baydemir I, Nikolka F, Bulut Ö, Ferreira A, Kilic G, Geckin B, Kramer R, Cuenca-Escalona J, Floor E, Báez-Magaña M, Matzaraki V, Deckers J, Anbergen T, van Elsas Y, Beldman T, Moorlag S, Charlotte J de Bree L, Spanou V, Andriopoulou T, Li Y, Karagianni E, Novakovic B, Sohrabi Y, Joosten L, Hiller K, Domínguez-Andrés J
Tapken I, Rahmel-Stein K, Ehlers C, Cieri F, Detering N, Schüning T, Bjelica B, Mindermann C, Neuhoff S, Schmitt L, Leo M, Hagenacker T, Illsinger S, Di Schiavi E, Graalmann T, Petri S, Kalinke U, Claus P
Amurri L, Reynard O, Ronco I, Déri D, Pályi B, Spanier J, Skerra J, Terceve O, Larcher T, Kalinke U, Kis Z, Horvat B, Iampietro M
We are investigating how the association of HCV with lipoproteins contributes to the persistence of the virus by influencing entry into liver cells and protecting against antibodies. The aim is to gain new insights for the development of an HCV vaccine.
Together with the Department of Structural Biology at the University of Lübeck, human, strongly neutralizing antibodies against HEV were identified and characterized for the first time. These showed a protective effect in the mouse model and are currently being further developed for clinical application, including mRNA-based application methods.
By applying statistical genetics methods to pathogen genome sequences, we aim to identify and validate genetic determinants of phenotypes such as pathogenicity, virulence and antibiotic resistance, e.g. in E. coli and P. aeruginosa.
Population genetic studies show that genetic variability between bacterial strains can influence the evolution of antimicrobial resistance. Using automated laboratory evolution (ALE), we are investigating how genetic backgrounds control AMR evolution.
Pathways to Infection Resilience
Prof. Naglaa Shoukry
University of Montreal
"Single-Cell RNA Sequencing Analysis of CD8+ T Cell-Mediated Protective Immunity During HCV Reinfection"
"Why is knowledge in regulatory science important for translational medicine and basic science?"

